iTeos Therapeutics (ITOS) Projected to Post Earnings on Thursday

Key Points

• iTeos Therapeutics (ITOS) is expected to report Q2 2025 earnings on August 14, with analysts predicting a loss of $0.94 per share.
• The stock price opened at $10.11 and has experienced significant fluctuations over the past year, with a 12-month low of $4.80 and a high of $18.13.
• Recent insider activity includes major shareholder Bioventures selling over 630,000 shares and CEO Michel Detheux disposing of 43,883 shares, reflecting a 22.19% decrease in his ownership.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.39). On average, analysts expect iTeos Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

iTeos Therapeutics Stock Down 0.2%

NASDAQ ITOS traded down $0.02 on Friday, reaching $10.11. The company had a trading volume of 1,018,707 shares, compared to its average volume of 936,258. The firm's 50 day moving average price is $10.11 and its 200 day moving average price is $8.14. iTeos Therapeutics has a 12 month low of $4.80 and a 12 month high of $18.13. The stock has a market capitalization of $386.91 million, a PE ratio of -2.16 and a beta of 1.49.

Insider Buying and Selling at iTeos Therapeutics

In other iTeos Therapeutics news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $8,317,363.86. Following the sale, the insider directly owned 3,452,797 shares in the company, valued at $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David Hallal sold 38,228 shares of the business's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,939,307 shares of company stock worth $16,202,116. Company insiders own 12.50% of the company's stock.

Hedge Funds Weigh In On iTeos Therapeutics

Several institutional investors have recently modified their holdings of the business. Strs Ohio acquired a new stake in iTeos Therapeutics during the 1st quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd bought a new position in iTeos Therapeutics during the 1st quarter worth approximately $67,000. AQR Capital Management LLC grew its position in shares of iTeos Therapeutics by 88.6% during the 1st quarter. AQR Capital Management LLC now owns 226,210 shares of the company's stock worth $1,350,000 after buying an additional 106,260 shares during the period. Finally, Jane Street Group LLC increased its stake in iTeos Therapeutics by 117.1% during the 1st quarter. Jane Street Group LLC now owns 21,438 shares of the company's stock valued at $128,000 after purchasing an additional 147,107 shares in the last quarter. Institutional investors own 97.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ITOS. HC Wainwright cut iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Leerink Partnrs lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Leerink Partners reiterated a "market perform" rating and issued a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Piper Sandler lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, July 21st. Finally, Raymond James Financial set a $12.00 price target on iTeos Therapeutics in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $15.50.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.